Answers are grounded in this paper and cite their sources.
Case illustrations report tooth resorption in patients receiving denosumab therapy, highlighting the need for early recognition and preventive strategies.
These cases illustrate a temporal association between DMAb therapy and MECRR but do not establish causality. Early recognition in patients receiving DMAb is important given the irreversible nature of MECRR. Interdisciplinary communication is important, and prospective and mechanistic studies are needed to clarify risk factors and develop preventive strategies.
No takes yet. Share an insight, caveat, or question.
Chu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: